Search - tctmd.com

Displaying 461 - 480 of 494

Sort: Relevancy | Date

News Industry News

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

May 24, 2011

News Industry News

Medtronic Resolute® Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients

May 20, 2011

News Industry News

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

May 18, 2011

News Industry News

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

May 17, 2011

News Daily News

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

May 16, 2011

News Daily News

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Leah Lawrence

April 26, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

News Conference News

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

Caitlin E. Cox

April 08, 2011

News Conference News

PRECOMBAT: PCI with Sirolimus Stent Equivalent to CABG in Left Main Disease

April 05, 2011

News Conference News

PLATINUM: Novel Platinum-Chromium DES Equals Outcomes of Xience V-Promus

L.A. McKeown

April 05, 2011

News Conference News

RESOLUTE US Looks at Latest-Generation Zotarolimus Stent

Caitlin E. Cox

April 04, 2011

News Industry News

Medtronic Resolute® Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies

April 04, 2011

News Industry News

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

April 03, 2011

News Industry News

Boston Scientific Announces its ACC 2011 Schedule

March 29, 2011

News Industry News

Medtronic to Unveil Pivotal U.S. Data on Resolute® Drug-Eluting Stent at ACC.11

March 28, 2011

News Industry News

Abbott to Present Data on Novel Vascular Technologies and XIENCE V® at ACC 2011

March 28, 2011

News Daily News

IVUS Supports Effectiveness of Novel Stent with Bioabsorbable Polymer

L.A. McKeown

March 10, 2011

News Daily News

Women Less Likely to Receive Evidence-Based Therapies Than Men

Jason Kahn

March 09, 2011

News Daily News

Many Cardiovascular Devices Approved by FDA Without Sex-Specific Data

L.A. McKeown

February 28, 2011

News Daily News

New Dual-Drug DES Adds Cilostazol to Boost Effectiveness of Paclitaxel

Jason Kahn

February 23, 2011

Advertisement

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

Medtronic Resolute® Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

PRECOMBAT: PCI with Sirolimus Stent Equivalent to CABG in Left Main Disease

PLATINUM: Novel Platinum-Chromium DES Equals Outcomes of Xience V-Promus

RESOLUTE US Looks at Latest-Generation Zotarolimus Stent

Medtronic Resolute® Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

Boston Scientific Announces its ACC 2011 Schedule

Medtronic to Unveil Pivotal U.S. Data on Resolute® Drug-Eluting Stent at ACC.11

Abbott to Present Data on Novel Vascular Technologies and XIENCE V® at ACC 2011

IVUS Supports Effectiveness of Novel Stent with Bioabsorbable Polymer

Women Less Likely to Receive Evidence-Based Therapies Than Men

Many Cardiovascular Devices Approved by FDA Without Sex-Specific Data

New Dual-Drug DES Adds Cilostazol to Boost Effectiveness of Paclitaxel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content